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ABSTRACT
Objective To systematically review the risk of mortality
associated with long term use of tiotropium delivered
using a mist inhaler for symptomatic improvement in
chronic obstructive pulmonary disease.
Data sources Medline, Embase, the pharmaceutical
company clinical trials register, the US Food and Drug
Administration website, and ClinicalTrials.gov for
randomised controlled trials from inception to July 2010.
Study selection Trials were selected for inclusion if they
were parallel group randomised controlled trials of
tiotropium solution using a mist inhaler (Respimat Soft
Mist Inhaler, Boehringer Ingelheim) versus placebo for
chronic obstructive pulmonary disease; the treatment
duration was more than 30 days, and they reported data
on mortality. Relative risks of all cause mortality were
estimated using a fixed effect meta-analysis, and
heterogeneity was assessed with the I
2 statistic.
Results Five randomised controlled trials were eligible
for inclusion. Tiotropium mist inhaler was associated
with a significantly increased risk of mortality
(90/3686 v 47/2836; relative risk 1.52, 95% confidence
interval, 1.06 to 2.16; P=0.02; I
2=0%). Both 10 µg (2.15,
1.03to4.51;P=0.04;I
2=9%)and5µg(1.46,1.01to2.10;
P=0.04; I
2=0%) doses of tiotropium mist inhaler were
associatedwithan increasedrisk of mortality. The overall
estimates were not substantially changed by sensitivity
analysis of the fixed effect analysis of the five trials
combined using the random effects model (1.45, 1.02 to
2.07; P=0.04), limiting the analysis to three trials of one
year’s duration each (1.50, 1.05 to 2.15), or the inclusion
ofadditionaldataontiotropiummistinhalerfromanother
investigational drug programme (1.42, 1.01 to 2.00). The
numberneededtotreatforayearwiththe5µgdosetosee
one additional death was estimated to be 124 (95%
confidence interval 52 to 5682) based on the average
control event rate from the long term trials.
Conclusions This meta-analysis explains safety concerns
byregulatoryagenciesandindicatesa52%increasedrisk
of mortality associated with tiotropium mist inhaler in
patients with chronic obstructive pulmonary disease.
INTRODUCTION
Chronic obstructive pulmonary disease is ranked the
fourth leading cause of death worldwide, with an esti-
mated 3.02 million in 2004.
1 Inhaled tiotropium bro-
mide, a long acting anticholinergic drug, is approved
for symptomatic benefit in patients with chronic
obstructive pulmonary disease. The treatment benefit
of inhaled tiotropium is a reduction in both the symp-
toms of dyspnoea and the risk for exacerbations of
chronic obstructive pulmonary disease.
2
Inhaled tiotropium is available in two formulations:
as a powder (Spiriva; Boehringer Ingelheim, Ger-
many)deliveredwithaHandihalerdevice(Boehringer
Ingelheim) and in solution as a mist delivered with the
Respimat Soft Mist Inhaler (Boehringer Ingelheim).
The mist inhaler is a propellant free device, which
generates a fine, slow moving cloud for inhalation.
3
Thedelivereddoseisindependentofinspiratoryeffort
and relatively unaffected by problems with breathing
manoeuvre compared with other devices. It is recom-
mended for use in patients who have poor manual
dexterity and therefore have difficulty using the
Handihaler.
4 Pharmacokinetic studies have shown
that compared with tiotropium 18 µg delivered by
the Handihaler, peak plasma concentrations with the
mist inhaler at doses of 5 µg and 10 µg were 35% and
threefold higher, respectively.
3 The mist inhaler is
available in 55 countries (320000 prescriptions com-
pared with 3 million for tiotropium powder dispensed
in England and Scotland in 2009),
56but this formula-
tion has yet to gain regulatory approval in the United
States.
7
Cardiovascular disease is the leading cause of mor-
bidity and mortality among patients with chronic
obstructive pulmonary disease.
8 The cardiovascular
effectsofinhaledanticholinergicshavebeenevaluated
inrecentstudies.
29-15Ameta-analysisof17randomised
controlled trials found a significantly increased risk of
major cardiovascular events (stroke, myocardial
infarction, and cardiovascular deaths, including sud-
den death) with inhaled anticholinergics (relative risk
1.58, 95% confidence interval 1.21 to 2.06; P<0.001).
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group receiving inhaled anticholinergics did not reach
significance(relativerisk1.26,95%confidenceinterval
1.0 to 1.61; P=0.06). However, the UPLIFT (Under-
standingthePotentialLong-TermImpactsonFunction
withTiotropium)trialofabout6000patientscompared
tiotropium powder with placebo
15 and did not report
any increase in mortality or cardiovascular events.
Somehaveconsidereddatafromthattrialtobereassur-
ing on the safety of tiotropium.
16 Patients receiving tio-
tropium withthe mist inhalerare, however,potentially
exposed to higher concentrations and the powder and
mist inhaler formulations are considered to be distinct
products.
7 In mid-December 2009 we came across
documents on the US Food and Drug Administration
website describing an advisory committee hearing on
tiotropium, held on 19 November 2009.
7 The main
focus of this hearing was the safety of tiotropium pow-
der, but we became aware of an accompanying discus-
sion concerning a numerical imbalance favouring
placebo in the mortality data for the tiotropium mist
inhaler. In view of these concerns about safety we sys-
tematicallyreviewedandmeta-analyseddatafromran-
domised controlled trials on the risk of mortality
associated with inhaled tiotropium delivered by the
mist inhaler compared with placebo in patients with
chronic obstructive pulmonary disease.
METHODS
In early 2010 we proceeded with formulating a review
question after finding out that tiotropium was licensed
for use by mist inhaler (Respimat Soft Mist Inhaler;
BoehringerIngelheim)inEurope,andareviewofmor-
tality concerns would therefore be clinically relevant
andwarranted.Furtherdiscussionofthereviewdesign
and protocol took place in the second quarter of 2010,
based on the specific purposeof using typical systema-
tic review and meta-analytical techniques to indepen-
dently evaluate the numerical imbalance in mortality
favouring placebo that had been discussed at the FDA
hearing. Final consensus on the protocol was reached
at the end of June 2010, and the conduct of this review
as per protocol began in July 2010.
Search strategy
We searched Medline and Embase from inception to
July 2010 (Ovid SP) using the search terms “tiotro-
pium.mp” AND “respimat.mp” where the suffix mp
indicatessearchingofthetitles,abstracts,subjecthead-
ings, substance name, and registry words. We did not
specify any language or population restrictions. To
identify unpublished studies we typed in the simple
search terms “respimat and tiotropium” in the search
boxes of several websites: Boehringer Ingelheim clin-
ical trials register, the FDA, and ClinicalTrials.gov up
to July 2010.
717-20 We also checked the bibliographies
of included studies and other systematic reviews,
which included looking at the included and excluded
trials picked up by the PubMed clinical trial filter
search for “tiotropium” from our previous meta-
analysis.
9
Study selection
Trials were identified and checked against inclusion
and exclusion criteria. Two reviewers (YKL and SS)
independentlyscanned all titles and abstracts that indi-
cated the study was a randomised controlled trial eval-
uating the use of tiotropium mist inhaler among
patients with chronic obstructive pulmonary disease.
Afterobtainingfullreportsofpotentiallyrelevanttrials,
the same reviewers independently assessed eligibility
from full text articles. Studies were selected for inclu-
sion if they were parallel group randomised controlled
trialsoftiotropiummistinhalercomparedwithplacebo
forthetreatmentofchronicobstructivepulmonarydis-
ease,iftreatmentdurationwasforatleast30days,andif
they provided numerical data on mortality.
Study characteristics and quality and risk of bias
assessment
We used a prespecified protocol to record the location
and duration of the randomised controlled trials (in
years),thedoseandfrequencyoftiotropiummistinha-
ler and placebo, mean age and sex of participants,
mean forced expiratory volume in one second
(FEV1), and smoking status.
TheCochranetoolkitwasusedfortheassessmentof
bias in evaluating each trial for the reporting of rando-
misation, allocation concealment, the use of blinding
ofparticipantsandstaff,andinformationonlosstofol-
low-up or withdrawal rates.
21 In accordance with the
Cochrane handbook of systematic reviews, we
assessed the quality of data on adverse effects by
recording how they were monitored and recorded by
the investigators.
21
Articles retrieved (n=57):
  PubMed and Embase (n=16)
  Boehringer Ingelheim (n=13)
  ClinicalTrials.gov (n=28)
Citations screened (n=57)
Excluded (n=43):
  Review articles (n=7)
  Crossover design (n=9)
  Not randomised controlled trial on chronic
    obstructive pulmonary disease (n=19)
  Duration <30 days (n=3)
  Still recruiting (n=2)
  Combination drugs or no placebo comparator (n=3)
Excluded due to deduplication and cross
matching with ClinicalTrials.gov study ID (n=8)
Potentially relevant trials reviewed in full text for eligibility (n=14)
Trials included in qualitative synthesis (n=6)
Studies included in quantitative synthesis (meta-analysis) (n=5)
1 trial not included in primary analysis, but evaluated in
sensitivity analysis as information on trial and participant
characteristics unavailable but data reported in regulatory documents
Fig 1 | Flow of participants through review
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The primary outcome measure was prespecified as
mortality from any cause. As a post hoc secondary
end point we evaluated deaths from cardiovascular
causes (myocardial infarction, stroke, cardiac death,
and sudden death).
Data abstraction
From the listings of safety data collected as part of
adverse event reporting for each study, two reviewers
(YKL and SS) independently and separately extracted
data(includingnoevents)ontheproportionofpatients
who died. To avoid potential duplication we checked
the regulatory reports with trials in the clinical trials
register when possible. Data on mortality were extra-
cted from regulatory documents and manufacturer’s
registry for trials that were unpublished. If a study
had multiple reports, we preferentially extracted data
from the version that had been reviewed or adjudi-
cated by the regulatory authority. Two reviewers
(YKL and SS) were independently involved in all
stages of study selection, data extraction, and quality
assessment. Discrepancies were resolved with 100%
agreement after rechecking the source papers and
further discussion among the reviewers, with full con-
sensus before drafting the article. If required, we con-
tactedauthorsforclarificationonspecificaspectsofthe
data.
Statistical analysis
We used RevMan 5.025 (Nordic Cochrane Center) to
carry out meta-analysis of the relative risk with 95%
confidence intervals for mortality. Statistical heteroge-
neity was assessed using the I
2 statistic, with values of
50% or more indicating a substantial level of
heterogeneity.
2223 We set statistical significance at a
two sided α of 0.05.
To avoid loss of information or choices related to
results from trials with multiple intervention arms (for
example, different doses of the drug), the Cochrane
handbook recommends that for dichotomous out-
comes, all relevant treatment arms can be amalga-
mated into one group by adding together the sample
sizes and numbers of people with events. Hence we
collapsed multiple intervention arms (different doses
oftiotropium)intrialswithmorethanoneintervention
group.
24 To enable us to estimate relative risks we
applied a continuity correction of 0.5 by the RevMan
Table 1 |Characteristics of tiotropium mist inhaler* in randomised controlled trials included in analysis of mortality
Study
Source Location
Duration
(weeks) Primary outcome
Cardiac and other
exclusions Druganddailydose
No of
partici-
pants
Mean (SD)
age (years) Males (%)
Mean (SD)
%predicted
FEV
1
Current
smokers
(%)
Voshaar et al
2008†
27 29
Multinational 12 FEV1 NA; condition that
could influence their
ability to participate
in study
Tiotropium 10 µg
(two puffs of 5 µg
each); tiotropium
5 µg( t w op u f f so f
2.5 µge a c h ) ;
placebo
93; 88; 91 64 (9); 64
(9); 63 (9)
72; 69; 69 39 (12); 40
(12); 42 (12)
37; 37; 43
Voshaar et al
2008†
28 29
Multinational 12 FEV1 NA; condition that
could influence their
ability to participate
in study
Tiotropium 10 µg
(two puffs of 5 µg
each); tiotropium
5 µg( t w op u f f so f
2.5 µge a c h ) ;
placebo
87; 92; 90 64 (9); 64
(9); 63 (9)
72; 69; 69 39 (12); 40
(12); 42 (12
37; 37; 43
Bateman et al
2010‡
30 32
Multinational 52 FEV1,F E V 1 and St
George’sr e s p i r a t o r y
questionnaire;
transitional
dyspnoea index and
exacerbation rate
NA; excluded those
with disease who
might be at risk
because of
participation
Tiotropium 10 µg
(two puffs of 5 µg
each); tiotropium
5 µg( t w op u f f so f
2.5 µge a c h ) ;
placebo
332; 332;
319
64.6 (8.4);
65(8.2);64.7
(8.9)
75.9;73.1;
79.3
37.7 (11.7);
38.0 (11.7);
37.5 (11.6)
35; 38; 36
Bateman et al
2010‡
31 32
Multinational 52 Predose FEV1 and St
George’sr e s p i r a t o r y
questionnaire;
transitional
dyspnoea index and
exacerbation rate
NA; excluded those
with disease who
might be at risk
because of
participation
Tiotropium 10 µg
(two puffs of 5 µg
each); tiotropium
5 µg( t w op u f f so f
2.5 µge a c h ) ;
placebo
335; 338;
334
65.6 (8.6);
64.4 (8.9);
65.7 (8.4)
73.4;73.3;
70.3
37.7 (11.7);
38.0 (11.7);
37.5 (11.6)
35; 38; 36
Bateman et al
2010
33 34
336 outpatient
centres in 31
countries
52 Predose FEV1 and
exacerbation
Unstable
arrhythmias;
myocardial
infarction in past
6 months or
congestive heart
failure in past
12 months
Tiotropium5 µg( t w o
puffsof2.5µgeach);
placebo
1989; 2002 64.8 (9.1);
64.8 (9.0)
78; 77 40; 40 35.7; 35.9
1205.14;
NC-
T00528996
35
Multinational 24 Trough FEV1 NA Tiotropium5 µg( t w o
puffsof2.5µgeach);
placebo
427; 429 NA; NA NA; NA NA; NA NA; NA
FEV1=forced expiratory volume in one second; NA=not available.
*Respimat Soft Mist Inhaler (Boehringer Ingelheim).
†Data from studies 251
27 and 252
28 were pooled in Voshaar et al.
29
‡Data from studies 254
30 and 255
31 were pooled in Bateman et al.
32
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arm. We chose the fixed effect Mantel-Haenszel
model as the primary method of analysis but carried
out a sensitivity analysis using the random effects
model. A Peto odds ratio analysis, which does not
require a continuity correction, was also carried out
because it provides the best confidence interval cover-
ageandhasgreaterpowerwhendealingwithlowevent
rates in specific circumstances where the fixed effect
assumptionisvalid.
25Additionalpredefinedsensitivity
analyses were done to explore the influence on effect
size of different doses of tiotropium (10 µg v 5 µg), the
effect of trial duration, and the influence of individual
trials. We estimated the annualised number needed to
treat for mortality associated with tiotropium mist
inhaler by applying the pooled relative risk from the
meta-analysis to the average control event rate in the
long term trials, using Visual Rx version 2.0.
26 The
number needed to treat for mortality is the number of
patients with chronic obstructive pulmonary disease
treated with tiotropium mist inhaler for one year,
rather than placebo, associated with one additional
death.
The study was carried out based on a prespecified
protocol, available from the authors.
RESULTS
Thesearchidentified57potentiallyrelevantarticlesor
trial protocols for tiotropium mist inhaler (fig 1). Five
placebo controlled randomised controlled trials of tio-
tropium mist inhaler were included in the meta-
Table 2 |Quality assessment of tiotropium mist inhaler* in randomised controlled trials included in analysis of mortality†
Study source
Sequence
generation
Allocation
concealment Adverse event monitoring
Drug dose (No of
participants)
Withdrawal
rate (%)
Loss to
follow-up (%)
Voshaar et al 2008‡
27 29 Randomised§ Adequate Adverse events, vital signs, 12 lead electrocardiogram,
routine laboratory tests, and physical examination
Tiotropium 10 µg (93);
tiotropium 5 µg (88);
placebo (91)
10; 8.8; 12.1 NA; NA; NA
Voshaar et al 2008
28 29 Randomised§ Adequate Adverse events, vital signs, 12 lead electrocardiogram,
routine laboratory tests, and physical examination
Tiotropium 10 µg (87);
tiotropium 5 µg (92);
placebo (90)
10; 8.8; 12.1 NA; NA; NA
Bateman et al 2010
30 32 Adequate,
computer
generated
Adequate Adverse events, vital signs, laboratory evaluations,
electrocardiogram and Holter testing, and physical
examination. Vital status of all patients (including those
who discontinued prematurely) was sought and all fatal
events were adjudicated to primary cause of death by
independent expert committee
Tiotropium 10 µg( 3 3 2 ) ;
tiotropium 5 µg( 3 3 2 ) ;
placebo (319)
16.5; 16.5; 28.5 1.5; 1.2; 3.4
Bateman et al 2010
31 32 Adequate,
computer
generated
Adequate Adverse events, vital signs, laboratory evaluations,
electrocardiogram and Holter testing, and physical
examination. Vital status of all patients (including those
who discontinued prematurely) was sought and all fatal
events were adjudicated as to primary cause of death by
independent expert committee
Tiotropium 10 µg( 3 3 5 ) ;
tiotropium 5 µg( 3 3 8 ) ;
placebo (334)
24.1; 17.7; 34.1 1.8; 1.4; 1.1
Bateman et al 2010
33 34 Adequate,
computer
generated
Adequate Adverse events, laboratory tests, vital signs, physical
examination, and electrocardiogram. Vital status of all
patients (including those who discontinued prematurely)
wassoughtand fataleventswere adjudicated asto primary
cause of death by independent expert committee.
Prospective adjudication of mortality
Tiotropium 5 µg (1989);
placebo (2002)
16; 19 1.1; 1.4
1205.14;
NCT00528996
35
Unclear Unclear Unclear Tiotropium 5 µg( 4 2 7 ) ;
placebo (429)
NA; NA NA; NA
NA=not available.
*Respimat (Soft Mist Inhaler; Boehringer Ingelheim).
†All trials were double blind.
‡Withdrawal rates for Voshaar et al 2008
27 29 and Voshaar et al 2008
28 29are reported together.
§Exact method not described but satisfactory as explicit statement regarding adequate allocation concealment.
Trial duration 12 weeks
  Voshaar et al 200827 29
  Voshaar et al 200828 29
Subtotal (95% CI)
Test for heterogeneity: χ2=0.05, df=1, P=0.82, I
2=0%
Test for overall effect: z=0.63, P=0.53
Trial duration 12 months
  Bateman et al 2010
30 32
  Bateman et al 2010
31 32
  Bateman et al 201033 34
Subtotal (95% CI)
Test for heterogeneity: χ2=2.65, df=2, P=0.27, I2=24%
Test for overall effect: z=2.22, P=0.03
Total (95% CI)
Test for heterogeneity: χ
2=2.78, df=4, P=0.59, I2=0%
Test for overall effect: z=2.30, P=0.02
1.52 (0.06 to 36.86)
2.53 (0.12 to 52.10)
2.02 (0.23 to 17.96)
1.17 (0.49 to 2.78)
4.47 (1.04 to 19.14)
1.38 (0.91 to 2.08)
1.50 (1.05 to 2.15)
1.52 (1.06 to 2.16)
1.3
1.3
2.6
18.4
5.2
73.8
97.4
100.0
0.05 0.2 1 5 20
Study
Less harm
with mist
inhaler
Less harm
with
placebo
Risk ratio
Mantel-Haenszel,
fixed (95% CI)
Risk ratio
Mantel-Haenszel,
fixed (95% CI)
Weight
(%)
1/181
2/179
3/360
17/664
18/673
52/1989
87/3326
90/3686
Tiotropium
mist inhaler
0/91
0/90
0/181
7/319
2/334
38/2002
47/2655
47/2836
Placebo
No of events/
No of participants
Fig 2 | Fixed effects meta-analysis of tiotropium delivered by mist inhaler (Respimat Soft Mist
Inhaler; Boehringer Ingelheim) and risk of mortality in randomised controlled trials of chronic
obstructive pulmonary disease
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27-34 One additional
six month trial from another investigational drug pro-
gramme in chronic obstructive pulmonary disease
reported preliminary data on mortality with tiotro-
piummistinhaler5µgcomparedwithplacebowithout
additionaldetailontrialcharacteristics.
35Thistrialwas
therefore not included in the primary analysis but was
evaluated in a sensitivity analysis. Table 1 shows the
characteristics of the trials.
The five trials included 6522 participants, of whom
3686 received tiotropium mist inhaler and 2836 a
placebo.
27-34 In these five trials, 2839 participants
received tiotropium 5 µg.
27-34 Additionally, four of
these trials also included another randomised arm in
which 847 participants received tiotropium mist inha-
ler 10 µg.
27-32 Two of the trials were short term, with a
duration of 12 weeks,
27-29 and three were long term,
with a duration of one year.
30-34
Allthetrialsweredoubleblind,withadequatealloca-
tion concealment (table 2).
27-34 Two of the short term
trials stated they were randomised but did not give the
specific method of sequence generation, although they
didstatethatinvestigatorsandparticipantswereblinded
to the process of randomisation.
27-29 However, since all
the trials were part of the same investigational pro-
gramme, it is unlikely that methods of randomisation
(remote computer generated lists of random numbers)
wouldbedifferent. Trial qualitywassatisfactory andall
fivetrialswerejudgedtobeatlowriskofbias(adequate
sequencegenerationorallocationconcealment,double
blinding, and clear reporting of loss to follow-up).
To reduce the chance of bias from differential dis-
continuation of participants between the tiotropium
and placebo arms, retrospective mortality ascertain-
ment on participants who discontinued the assigned
intervention was carried out at the request of regula-
tory agencies for the two long term trials, after safety
concerns about tiotropium.
30-3236 The cause specific
mortalityestimatesfromthesetwotrials
30-32werecom-
bined and adjudicated in the FDA review.
720 Subse-
quently, one long term trial of tiotropium mist inhaler
ascertained mortality prospectively on all randomised
participants, including those who withdrew from the
trial.
3334
Primary outcome
Table 3 shows the data on mortality from the rando-
mised controlled trials. Overall, the tiotropium mist
inhaler was associated with a significantly increased
risk of mortality compared with placebo (five trials,
90/3686 v 47/2836; relative risk 1.52, 95% confidence
interval 1.06 to 2.16; P=0.02).
27-34 Evidence of statisti-
cal heterogeneity for mortality was lacking among the
trials (I
2=0%).
27-34
Because the trials were of different duration a forest
plotillustratesthetreatmenteffectsfortrialsuptothree
months and the longer term trials for one year (fig 2).
Table 3 |Data on mortality and cardiovascular death from randomised controlled trials of tiotropium mist inhaler*
Study source Drug dose, or placebo
No of
participants
All cause
mortality Cardiovascular death
Voshaar et al 2008
27 29 Tiotropium 10 µg; tiotropium 5 µg;
placebo
93; 88; 91 1; 0; 0 0; 0; 0
Voshaar et al 2008
28 29 Tiotropium 10 µg; tiotropium 5 µg;
placebo
87; 92; 90 1; 1; 0 0; 0; 0
Bateman et al 2010
30 32 Tiotropium 10 µg; tiotropium 5 µg;
placebo
332; 332; 319 8; 9; 7 Study 254/255 combined 5 µga n d1 0µg
cardiovascular deaths (n=8): due to cardiac
failure (n=1), myocardial infarction/coronary
insufficiency (n=6), and stroke (n=1)
Bateman et al 2010
31 32 Tiotropium 10 µg; tiotropium 5 µg;
placebo
335; 338; 334 11; 7; 2 Cardiovascular death with placebo: stroke
(n=1)
Bateman et al 2010
33 34 Tiotropium 5 µg; placebo 1989; 2002 52; 38 22; 12
1205.14;
NCT00528996
35
Tiotropium 5 µg; placebo 427; 429 2; 5 NA; NA
*Respimat Soft Mist Inhaler (Boehringer Ingelheim).
Tiotropium 5 µg
  Voshaar et al 200827 29
  Voshaar et al 200828 29
  Bateman et al 201030 32
  Bateman et al 2010
31 32
  Bateman et al 2010
33 34
Total (95% CI)
Test for heterogeneity: χ2=1.54, df=3, P=0.67, I2=0%
Test for overall effect: z=2.03, P=0.04
Tiotropium 10 µg
  Voshaar et al 200827 29
  Voshaar et al 200828 29
  Bateman et al 2010
30 32
  Bateman et al 201031 32
Total (95% CI)
Test for heterogeneity: χ2=3.31, df=3, P=0.35, I2=9%
Test for overall effect: z=2.03, P=0.04
Not estimable
2.94 (0.12 to 1.12)
1.24 (0.47 to 3.28)
3.46 (0.72 to 16.53)
1.38 (0.91 to 2.08)
1.46 (1.01 to 2.10)
2.94 (0.12 to 71.15)
3.10 (0.13 to 75.14)
1.10 (0.40 to 2.99)
5.48 (1.22 to 24.55)
2.15 (1.03 to 4.51)
1.1
15.0
4.2
79.7
100.0
5.0
4.8
70.4
19.8
100.0
0.05 0.2 1 5 20
Study
Less harm
with mist
inhaler
Less harm
with
placebo
Risk ratio
Mantel-Haenszel,
fixed (95% CI)
Risk ratio
Mantel-Haenszel,
fixed (95% CI)
Weight
(%)
0/88
1/92
9/332
7/338
52/1989
69/2839
1/93
1/87
8/332
11/335
21/847
Tiotropium
mist inhaler
0/91
0/90
7/319
2/334
38/2002
47/2836
0/91
0/90
7/319
2/334
9/834
Placebo
No of events/
No of participants
Fig 3 | Meta-analysis of tiotropium delivered by mist inhaler (Respimat Soft Mist Inhaler;
Boehringer Ingelheim) 5 µga n d1 0µg and risk of mortality in randomised controlled trials of
chronic obstructive pulmonary disease
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three trials of 12 months’ duration (1.50, 1.05 to 2.15;
P=0.03; I
2=24%).
30-34
Effect of different doses of tiotropium
Compared with placebo, tiotropium 5 µg was asso-
ciated with a 46% increased risk of mortality in the
five trials (1.46, 1.01 to 2.10; P=0.04; I
2=0%), whereas
the 10 µg dose was associated with a doubling of the
relative risk in four trials (2.15, 1.03 to 4.51; P=0.04;
I
2=9%), (fig 3).
27-32 A direct comparison of the two
dosesusinga fixed effectmeta-analysisfrom fourtrials
showed an increased risk of overall mortality asso-
ciated with 10 µg tiotropium that did not reach signifi-
cance (1.23, 0.66 to 2.30; P=0.51).
27-32
Sensitivity analysis
Peto method versus Mantel-Haenszel method—Sensitivity
analysisbasedonthePetooddsratioforoverallmortal-
ity in the five included studies showed results similar to
the Mantel-Haenszel fixed effect analysis: Peto odds
ratio 1.53 (95% confidence interval 1.08 to 2.16), P=
0.02.
27
Fixed effect versus random effects—Sensitivity analysis
using the random effects model for overall mortality
in the five trials showed results similar to the fixed
effect model: relative risk 1.45 (95% confidence inter-
val 1.02 to 2.07), P=0.04.
27-34
Inclusion of additional trial—The inclusion of data
from the additional trial
35 did not significantly change
theoverallresults(sixtrials,1.42,1.01to2.00;P=0.05;
fig 4), but reduced the relative risk for the 5 µg dose to
1.36 (0.96 to 1.94; P=0.09).
Secondary outcome
Although the numbers for cardiovascular death were
sparse (table 3), tiotropium was associated with a sig-
nificantly increased relative risk in the five trials (2.05,
1.06 to 3.99; P=0.03; I
2=0%; fig 5).
23-30
Number needed to treat for mortality
Applying the relative risk estimate of 1.46 (95% confi-
dence interval 1.01 to 2.10) from the meta-analysis of
the5µgdosetothecontroleventrateof1.76%peryear
for mortality in the long term trials, the annualised
number needed to treat for mortality associated with
tiotropiumwasestimatedat124(95%confidenceinter-
val 52 to 5682)—that is, one excess death would be
expected for every 124 patients treated with 5 µgo f
tiotropium for one year.
DISCUSSION
Thismeta-analysisshowsthattiotropiumdeliveredwith
the Respimat Soft Mist Inhaler (Boehringer Ingelheim)
isassociatedwithastatisticallysignificantincreasedrisk
of mortality in patients with chronic obstructive pul-
monary disease. Our findings raise the possibility of a
dose-responseeffect,althoughtherelativelysparsedata
prevent us from drawing firm conclusions.
Strengths of the study
Thevalidityofourpooledestimateswereenhancedby
several features of our analysis. Our data represent the
complete set of parallel group trials of more than
30 days’ duration carried out by the manufacturer for
tiotropium mist inhaler compared with placebo that
was submitted to the US FDA. The trials were done
in a standardised manner by a single sponsor and the
riskofbiaswasgenerallylow,thusenhancingthevalid-
ity of pooling in a meta-analysis. Trial investigators
managed complete capture of the mortality outcome
in the long term trials, and took onerous stepsto ascer-
tain the vital status of all randomised patients, even if
they had discontinued treatment, thus minimising the
risk of bias from differential follow-up and selective
outcome reporting. The finding of the increased risk
remains robust to various sensitivity analyses such as
the use of the random effects model and the inclusion
of preliminary data from another unpublished trial.
Alternative explanations exist for these unfavour-
able findings. In one unpublished study, the increase
inmortalitywasattributedbythesponsortoabaseline
imbalanceinriskcreatedbyrandomisation,oranunu-
sually low rate of mortality in the placebo arm of these
trials.
37However,asystematicfailureofrandomisation
is highly unlikely, as both the tiotropium and the pla-
cebo groups had comparable baseline characteristics
in all the trials, with adequate allocation concealment
during randomisation. It is unclear why patients using
theplaceboinhalerswouldhavea33%lowermortality
thanthosereceivingactivetreatment.Theexcessdeath
Trial duration 3-6 months
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Fig 4 | Sensitivity analysis of tiotropium delivered by mist inhaler (Respimat Soft Mist Inhaler;
Boehringer Ingelheim) and risk of mortality in randomised controlled trials of chronic
obstructive pulmonary disease after including data from additional trial
35
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ofthedatatosensitivityanalysisandgenerallylowrisk
ofbiasindicatesthatthisisasafetysignalmeritingboth
caution and further investigation.
Biological plausibility
TheLungHealth Studyreporteda significantlyhigher
rate of admissions to hospital for malignant arrhyth-
mias in participants with mild to moderate chronic
obstructive pulmonarydiseaserandomisedtotheanti-
cholinergic inhaler.
38 Inhaled tiotropium is absorbed
systemically and excreted in the urine.
39 Orally admi-
nistered anticholinergic drugs are associated with car-
diac arrhythmias.
40 This information provides a
biologically plausible mechanism for anticholinergic
inhalers causing sudden cardiac death. Patients with
pre-existing arrhythmias seem to be at the highest
risk of death with tiotropium mist inhaler.
37
Patients using the mist inhaler may have clinically
relevant,higherpeakconcentrationsandoverallexpo-
suretotiotropium,providingaplausiblemechanismof
differential toxicity and a dose-response relation when
compared with the powder formulation used with the
Handihaler (Boehringer Ingelheim). In one study, the
peakplasmaconcentration(Cmax)oftiotropiumpow-
der 18 µg was 8.49 pg/mL comparedwith 11.5 pg/mL
and 26.4 pg/mL for 5 µg and 10 µg of the mist inhaler,
respectively, although the statistical significance of
these data was not reported.
3 Similarly, the area
under the curve for overall exposure to tiotropium
showed that patients receiving tiotropium powder
18 µg had a lower mean exposure to the drug: 55.9
pg h/mL compared with 64.7 pg h/mL and 146 pg h/
mLfor5µgand10µgofthemistinhaler,respectively.
Comparison with other reports
Our finding should be interpreted in the context of
other recent reports.
41-43 A meta-analysis driven
mainly by data from the UPLIFT trial reported no sig-
nificant increase in cardiovascular events with
tiotropium.
42 However, 18 of the 19 trials were based
on the powder formulation, and only one small study
on the mist inhaler
29 contributed data to the meta-
analysis. Another meta-analysis of 30 trials of
tiotropium
43 indicated that the drug was associated
with reductions in cardiovascular events or mortality,
but a separate assessment of the two different products
(powderandmistinhaler)wasnotreported.Moreover,
thismeta-analysisdidnotincludethelargesttrialofthe
mist inhaler,
33 and it is unclear if deathsamong partici-
pants who withdrew prematurely in three trials were
considered.
283031
Limitations of the review
Our analysis has limitations, which mainly reflect the
qualityofreporteddata.Differencesexistinthepopula-
tionsstudied,dosesoftiotropiumusingthemistinhaler,
and length of follow-up. The estimates are imprecise
owingtothe fairlyloweventrates.Wecouldnot exam-
inecausespecificmortalityingreatdepthbecauseofthe
lack of details in the reported data. Similarly, cardio-
vascular death was not a prespecified outcome, and
the analysis relies on post hoc classification and adjudi-
cation.Wedidnothaveaccesstoindividualpatientdata
to allow analyses of time to event.
Unanswered questions and future research
Anongoingtwoyearheadtoheadtrialbetweentiotro-
piummistinhaler2.5µg(twopuffsof1.25µgeach)and
tiotropium powder 5 µg (two puffs of 2.5 µg each) and
18 µg has been designed to investigate these safety
issues and should further clarify these uncertainties.
44
The primary outcomes include exacerbation of
chronic obstructive pulmonary disease and overall
mortality as well as a secondary outcome measure of
major adverse cardiovascular events. Clinical trials of
chronic obstructive pulmonary disease should be
designed to include both efficacy and cardiovascular
disease mortality (including sudden death) as co-pri-
maryoutcomemeasures.Furtherstudiesshouldclarify
the effects of long acting inhaled anticholinergics on
cardiovasculareventsandmortalityamongvulnerable
subgroups at the highest risk of systemic anti-
cholinergic effects, such as those with pre-existing
arrhythmias, cardiomegaly, or moderate to severe
renal impairment who are typically excluded from
trials. A precautionary warning about this possible
association has been added to the package insert for
Respimat in New Zealand.
45 The UK Medicines and
Healthcare Products Regulatory Agency has also pro-
vided recent guidance on this concern.
4647
Conclusions
Our meta-analysis explains safety concerns by regula-
tory agencies regarding the possibility of an increased
risk of mortality associated with tiotropium mist inha-
ler in patients with chronic obstructive pulmonary dis-
ease. In accordance with guidancefrom the Medicines
and Healthcare Products Regulatory Agency, clini-
cians should inform patients about the possibility of
thisincreasedrisk and exercisecautionwhenprescrib-
ing tiotropium mist inhaler, particularly in patients
with possible underlying cardiac disease.
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Not estimable
Not estimable
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Fig 5 | Meta-analysis of tiotropium delivered by mist inhaler (Respimat Soft Mist Inhaler;
Boehringer Ingelheim) and risk of cardiovascular death in randomised controlled trials
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